Shandong Pharmaceutical Glass Co (SHSE:600529) EBIT: ¥804 Mil (TTM As of Mar. 2026)


SHSE:600529 Shandong Pharmaceutical Glass Co Ltd SHSE:600529
83 GF Score
Price ¥18.29
GF Value ¥23.98
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shandong Pharmaceutical Glass Co EBIT?

Shandong Pharmaceutical Glass Co SHSE:600529 +2.01% 83 EBIT is ¥804 Mil as of Mar. 2026. GuruFocus rates SHSE:600529 with a GF Score™ of 83/100 and a GF Value™ of ¥23.98 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Shandong Pharmaceutical Glass Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥240 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥804 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Pharmaceutical Glass Co's annualized ROC % for the quarter that ended in Mar. 2026 was 15.51%. Shandong Pharmaceutical Glass Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Pharmaceutical Glass Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.52%.

Shandong Pharmaceutical Glass Co  (SHSE:600529) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Pharmaceutical Glass Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1075.336 * ( 1 - 15.89% )/( (5789.73 + 5871.118)/ 2 )
=904.4651096/5830.424
=15.51 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10043.77 - 1508.961 - ( 2745.079 - max(0, 1601.2 - 6012.161+2745.079))
=5789.73

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10136.628 - 1524.291 - ( 2741.219 - max(0, 1611.973 - 6106.79+2741.219))
=5871.118

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Pharmaceutical Glass Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=959.744/( ( (3678.005 + max(1088.195, 0)) + (3655.236 + max(1190.009, 0)) )/ 2 )
=959.744/( ( 4766.2 + 4845.245 )/ 2 )
=959.744/4805.7225
=19.97 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(896.715 + 1695.694 + 82.880999999999) - (1508.961 + 0 + 78.134)
=1088.195

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1008.968 + 1670.502 + 107.054) - (1524.291 + 0 + 72.224)
=1190.009

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Pharmaceutical Glass Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=804.359/9438.663
=8.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Pharmaceutical Glass Co EBIT Related Terms

Shandong Pharmaceutical Glass Co EBIT Historical Data

* Premium members only.

The historical data trend for Shandong Pharmaceutical Glass Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Pharmaceutical Glass Co EBIT Chart

Shandong Pharmaceutical Glass Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 685.96 705.45 911.05 1,110.83 831.34

Shandong Pharmaceutical Glass Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 266.92 174.64 206.85 182.93 239.94

SHSE:600529 vs SW, PKG, IP: EBIT Comparison

For the Packaging & Containers subindustry, Shandong Pharmaceutical Glass Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Pharmaceutical Glass Co EV-to-EBIT vs Packaging & Containers Industry

For the Packaging & Containers industry and Consumer Cyclical sector, Shandong Pharmaceutical Glass Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Pharmaceutical Glass Co's EV-to-EBIT falls into.


SHSE:600529
83GF Score
Shandong Pharmaceutical Glass Co Ltd SHSE:600529
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Pharmaceutical Glass Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥804 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥804 Mil mean?
Shandong Pharmaceutical Glass Co (SHSE:600529) has a EBIT of ¥804 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Pharmaceutical Glass Co.
Is Shandong Pharmaceutical Glass Co's EBIT too high?
Shandong Pharmaceutical Glass Co's current EBIT is ¥804 Mil. Overall, Shandong Pharmaceutical Glass Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Pharmaceutical Glass Co's EBIT compare to SW and PKG?
Shandong Pharmaceutical Glass Co's EBIT of ¥804 Mil can be compared against companies in the Packaging & Containers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Packaging & Containers company?
A good EBIT depends on the Packaging & Containers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Pharmaceutical Glass Co. Shandong Pharmaceutical Glass Co's current EBIT is ¥804 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Pharmaceutical Glass Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co (SHSE:600529) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.98, compared to a current price of ¥18.29 — trading 23.7% below its estimated fair value. The current EBIT is ¥804 Mil. Shandong Pharmaceutical Glass Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shandong Pharmaceutical Glass Co (SHSE:600529), the current EBIT is ¥804 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Pharmaceutical Glass Co (SHSE:600529) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co stock appears to be undervalued. The current stock price of ¥18.29 is trading 23.7% below its estimated GF Value™ of ¥23.98. GuruFocus considers Shandong Pharmaceutical Glass Co to be Modestly Undervalued.

Key valuation signals for SHSE:600529:

  • EBIT: ¥804 Mil
  • GF Value™: ¥23.98 vs. price of ¥18.29 (23.7% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600529 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Pharmaceutical Glass Co Business Description

Address Yaobo Road, Yiyuan County, Zibo, Shandong, CHN, 256100
Shandong Pharmaceutical Glass Co Ltd is a pharmaceutical glass packaging product company. Its pharmaceutical glass packaging products and butyl rubber series products which service object of pharmaceutical, food, daily necessities industries. The products include for moulded injection vial for antibiotics series, tubular glass vial series, amber glass bottle series, neutral borosilicate glass bottle series, infusion bottle series, cosmetic bottles series, food bottles series, butyl rubber stopper series, prefillable syringes series, and aluminum-plastic cap series.
83GF Score

Get the complete analysis for SHSE:600529

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥18.29
Price
¥23.98
GF Value